Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…
CYTOKINETICS INC
Last earnings +16.7% on 2026-05-05
Revenue grew 376.6% YoY; but unprofitable (net margin -891.6%).
Rules-based read computed from SEC figures — no Anthropic key set. Add ANTHROPIC_API_KEY to .env.local for a full Claude analysis.
CYTOKINETICS INC shows $88.0M in FY2025 revenue (+376.6% YoY), a -891.6% net margin, and 119.0% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
Sources: SEC EDGAR (CIK 0001061983, latest 10-Q filed 2026-05-05) · EODHD · rules-based read · as of 6/18/2026, 5:10:59 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $70.4M | $94.6M | $7.53M | $18.5M | $88.0M |
| Gross profit | — | — | — | — | — |
| Operating income | -$186M | -$324M | -$496M | -$536M | -$612M |
| Net income | -$215M | -$389M | -$526M | -$590M | -$785M |
| Diluted EPS | -$2.80 | -$4.33 | -$5.45 | -$5.26 | -$6.54 |
| Net margin | -305.7% | -411.2% | -6988.6% | -3191.1% | -891.6% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
501 tracked peers · median
Last 90 days: 0 open-market buys · 6 sales
| 2026-06-15 | Blum Robert I President & CEO | Sell | 7.50K @ $70.46 | $528K |
| 2026-06-09 | Malik Fady Ibraham EVP Research & Development | Exercise | 3.50K @ $7.80 | $27.3K |
| 2026-06-09 | Malik Fady Ibraham EVP Research & Development | Sell | 3.50K @ $67.98 | $238K |
| 2026-06-01 | Kaye Edward M. MD Director | Sell | 2.93K @ $76.09 | $223K |
| 2026-06-01 | Callos Andrew EVP, Chief Commercial Officer | Exercise | 15.0K @ $23.26 | $349K |
| 2026-06-01 | Callos Andrew EVP, Chief Commercial Officer | Sell | 15.0K @ $74.08 | $1.11M |
| 2026-06-01 | PARSHALL B LYNNE Director | Sell | 5.00K @ $74.08 | $370K |
| 2026-05-27 | Blum Robert I President & CEO | Sell | 7.50K @ $77.21 | $579K |
| 2026-05-27 | Bhanji Muna Director | Award | 2.85K | |
| 2026-05-27 | Daly James M Director | Award | 2.85K |